S promise of long-term survival for patients with nonsmall

Size: px
Start display at page:

Download "S promise of long-term survival for patients with nonsmall"

Transcription

1 Aggressive Surgical ntervention in N Non-Small Cell Cancer of the Lung Yoh Watanabe, MD, Junzo Shimizu, MD, Makoto Oda, MD, Yoshinobu Hayashi, MD, Shinichiro Watanabe, MD, Yasuhiko Tatsuzawa, MD, Takashi wa, MD, Masayuki Suzuki, MD, and Tsutomu Takashima, MD Departments of Surgery and Radiology, Kanazawa University School of Medicine, Kanazawa, Japan An aggressive attitude toward surgical treatment was taken in patients with N non-small cell lung cancer in the past years. Computed tomographic scanning was employed in the diagnosis of N disease, and had a true-positive rate of 7%. Among patients with N disease detected by computed tomographic scanning, surgical intervention was attempted except for those with unresectable disease. Of patients with clinical N disease, underwent surgical exploration: patients had only an exploratory thoracotomy, patients underwent a curative operation, and had a noncurative operation. The overall -year survival rate of these patients was 6% and that of curatively resected patients was %. There were 7 patients whose N disease was not recognized before operation. The -year survival rate of this group was % overall and % in curatively resected cases. The overall -year survival rate of patients with N disease who underwent resection (6 with clinical N disease and 7 with clinically unrecognized N disease) was 7%, and that of the 8 patients undergoing curative operations was %. An aggressive attitude toward surgical intervention can be advocated for patients with N disease on the basis of our present results. (Ann Thorac Surg ;:-6) urgical treatment is the only method that holds the S promise of long-term survival for patients with nonsmall cell lung cancer, and the role of the surgeon is to select appropriate surgical candidates so as to ensure the greatest possible benefit to the individual cancer patients. There are differences of opinion regarding the indications for operation in patients with ipsilateral mediastinal lymph node metastasis (N disease) discovered at thoracotomy. Some authors insist that all patients having preoperatively detected N disease should not be operated on. Others say that surgical candidates who may have N disease should undergo mediastinoscopy and that those with histologically proven N disease should be excluded from thoracotomy [-6]. n contrast, there are some authors who believe that N disease does not contraindicate surgical resection [7-. Recently, Shields [lo] reported on the significance of N disease in non-small cell lung carcinoma. He collected and analyzed many papers on the results of treatment in patients with N disease and concluded that a small subset of patients with resectable N disease discovered at thoracotomy or mediastinoscopy should be considered as potential surgical candidates. Unfortunately, the survivors from this group of patients represent only % to 6% of all patients with N disease, so N disease must be considered to have a very poor prognosis. Accepted for publication Oct,. Address reprint requests to Dr Watanabe, Department of Surgery, Kanazawa University School of Medicine, - Takara-machi, Kanazawa, Japan. t has been our policy that all patients with marginally resectable N non-small cell lung carcinoma should be carefully evaluated with the possibility of surgical therapy in mind. As an operative procedure for N disease, extensive mediastinal lymph node dissection with some modification of the standard operation was done in the past years. As a result, aggressive resection has been performed in patients with N disease whenever it was thought to be feasible after the preoperative work-up. At our institution, the routine use of computed tomographic (CT) scanning in the preoperative evaluation of N disease was started in 8. This paper reports a clinical analysis of patients having N disease detected by preoperative CT scanning, by thoracotomy, or by postsurgical analysis of the resected specimens. Material and Methods Since 8, all admitted lung cancer patients were examined by chest CT scanning to evaluate their T and N factors. n addition, evaluation of metastases to the brain, bone, and abdominal organs was performed by CT scanning, radioisotope scanning, and ultrasonography. Lymphadenopathy was routinely investigated by CT scanning and mediastinal lymph nodes larger than mm along their short axis (except for subcarinal nodes) were defined as metastatic lymph nodes (N disease). For subcarinal lymph nodes, nodes larger than mm along their short axis were defined as metastatic nodes. Calcified lymph nodes were not defined as metastatic nodes, even if their sizes fulfilled the criteria for N disease. by The Society of Thoracic Surgeons -7//$.

2 WATANABE ET AL N NON-SMALL CELL LUNG CANCER Ann Thorac Surg ::-6 Table. Patients With Clinical N Disease and Their Postoperative Diagnoses Clinically N Curative Noncurative No (n = 78) Oueration Oueration Resection" Total Postoperatively NO (n = ) T- NO MO T NO MO T NO MO T NO M Postoperatively N (n = 6) T- N MO T N MO T N MO T N M Postoperatively N (n = ) T N MO T N MO T N MO T N MO T N M T N M T N M T N M Postoperatively N (n = ) T- N MO T N MO T N MO T N M T N M Total a Nine patients with exploratory thoracotomy without resection were included. Staging of patients not undergoing resection was performed clinically. From 8 to June, 7 patients with proven non-small cell lung cancer were admitted to the Department of Surgery at Kanazawa University School of Medicine. All patients underwent CT scanning for evaluation of the N factors and the other factors needed for staging of the disease. There were 78 patients who were clinically diagnosed as having N disease (cn) by preoperative CT scanning (Table ). Among the patients who were shown to have N disease by preoperative CT scanning, surgical intervention was attempted, except in the following cases: patients with distant metastases to extrathoracic organs; patients with unresectable T lesions, such as malignant pleural effusion, or extensive invasion of the great vessel, vertebral bodies, trachea, or carina; patients with bulky N disease; and patients regarded as unsuitable for other reasons. Among the 78 cn patients, were operated on and (7% of cn patients) underwent resection. Nine patients only had an exploratory thoracotomy because of the extensiveness of their disease. On pathological examination of the resected specimens, patients still had N disease (postsurgical histopathological N, pn), comprising 7% (/) of the N patients undergoing exploration. f N disease that was not detected by preoperative CT scanning was discovered at thoracotomy by examination of frozen section, resection still proceeded unless other unresectable disease existed. After operation, all of the dissected lymph nodes were sent for pathological examination [ll]. There were 7 patients whose preoperative diagnosis was NO or N, but who were verified to have N disease by intraoperative or postoperative pathology studies (Table ). A total of pn patients have been accumulated in the past years: 6 patients were cn patients and 7 were cno or cn patients. n addition, there were 8 cn patients in whom resection was not performed. Although N disease could not be verified by pathological examination in these unresected cases, they were defined as having actual N disease. The histology of these 6 N patients is shown in Table. Routine systematic dissection of the mediastinal lymph nodes was performed in every case (even if the preoperative evaluation was NO or Nl), in accordance with the lymph node map proposed by the Japan Lung Cancer Society []. On the right side, the mediastinal pleura was longitudinally incised along the trachea and esophagus from the apex to the base of the right hemithorax. For node dissection in the superior mediastinum, the azygos vein was cut to mobilize the trachea, esophagus, and superior vena cava. All of the accessible lymph nodes in the superior mediastinurn, ie, the superior mediastinal (#l), paratracheal (#), pretracheal (#), retrotracheal (#p), and tracheobronchial angle (#) nodes, were removed with the surrounding fat pad. The node anterior to the superior vena cava (#a) was also routinely removed, Table. Preoperative Staging of 7 Patients With Postoperatively N Disease That Was Not Detected by Preoperative Evaluation Preoperative Curative Noncurative Staging Operation Operation Total Stage T NO MO 7 T NO MO Stage T N MO Stage A T NO MO 7 T N MO Stage B T NO MO T N MO Total 6 7

3 Ann Thorac Surg!;:-6 WATANABE ET AL N NON-SMALL CELL LUNG CANCER Table. Histological Diagnosis and Operative Radicality of 7 Patients With N Disease Epidermoid Adenosquamous Large Cell Mucoepidermoid Diagnosis Adenocarcinoma Carcinoma Carcinoma Carcinoma Carcinoma Total Clinically NO- (n = 7) Curative operation Noncurative operation No resection Clinically N (n = ) Curative operation Noncurative operation No resection Total with N disease (n = 7) Curative operation Noncurative operation No resection Total including thymic tissue. By these procedures all of the lymph nodes and fat pad located around the subclavian artery, trachea, right main bronchus, ascending aortic arch, superior vena cava, and upper thoracic esophagus could be completely removed. For node dissection in the inferior mediastinum, the incised posterior mediastinal pleura was reflected and the pulmonary ligament was cut to expose the tracheal bifurcation, both main bronchi, the pericardium, and the lower thoracic esophagus. All of the lymph nodes in this compartment, ie, subcarinal (#7), paraesophageal (#8), and pulmonary ligament (#) nodes, were dissected out with their surrounding fat pad. On the left side, lymph node dissection in the inferior mediastinum was performed similarly to that on the right side, excluding subcarinal node dissection. However, in the superior mediastinum, there were great anatomical limitations on node dissection, in contrast to the right side. As the routine procedure before the present series, the mediastinal pleura was incised just beneath the aortic arch and the subaortic (#), paraaortic (#6), subcarinal (#7), paraesophageal (#8), pretracheal (#), and paratracheal (#) nodes were removed as far as it was possible. However, in the present series, the operative procedure was modified to allow more complete dissection of the lymph nodes in the left superior mediastinum. When left-sided N lung cancer was diagnosed by preoperative CT scanning or discovered at thoracotomy, two kinds of adjunctive procedures were performed in addition to the previous dissection method. For the earlier half of this series, the aortic arch and part of the descending aorta were mobilized by cutting a few intercostal arteries to allow more extensive removal of the superior mediastinal nodes. By this procedure, lymph nodes,, and p were completely dissected. n the later half of this series, to allow a far more extensive node dissection, median sternotomy was performed after procedures in the left hemithorax had been completed using the left posterolatera approach []. By this procedure, nodes,,, a,, and 7 in the ipsilateral side and also mediastinal and hilar lymph nodes in the contralateral side could be completely dissected. For the comparison of surgical results, operative radicality was divided into two categories. Curative operations were defined as those in which the tumor and accessible mediastinal lymph nodes were completely removed, whereas noncurative operations were those in which the tumor, metastatic lymph nodes, or both were incompletely excised. Staging of all the patients was performed using the new TNM classification proposed by the Union nternationale Contre le Cancer in 86 []. There exists disagreement regarding the definition of M disease in the case of intrapulmonary metastasis. The American Joint Committee defines pulmonary metastasis only to the contralateral lung as M disease [], whereas the Union nternationale Contre le Cancer [] and the Japan Lung Cancer Society [] define both ipsilateral and contralateral pulmonary metastases as M disease. n this study, we adopted the latter definition. All of the patients with postsurgical stage V disease in the present series (see Table ) had microscopic ipsilateral pulmonary metastases, which were discovered at postsurgical examination of the resected lung. Radiation therapy was not done as routine postoperative treatment but was performed in some patients who underwent noncurative operations or in those in whom mediastinal nodal recurrence developed. For calculation of the survival rate, we included six postoperative deaths occurring within days of operation: all of them occurred in cn-pn patients, with being in the curative operation group and the other in the noncurative operation group. The survival rate was calculated by the Kaplan-Meier method and statistical significance was evaluated by the Cox-Mantel and generalized Wilcoxon tests. When these two tests gave values of p less than., the difference was defined as statistically significant.

4 6 WATANABE ET AL N NON-SMALL CELL LUNG CANCER Ann Thorac Surg ;:-6 * cn explored (%) (%)... 6(%) ( 6%) Fig. Postoperative staging of the N factor in clinical N patients submitted for surgical exploration. (* Nine patients having an exploratory thoracotomy were included.) (c = clinical stage; p = postoperative stage.) Results Diagnostic Value of Preoperative Computed Tomographic Scanning in Assessing N Disease This evaluation was made only in the resected non-small cell lung cancer patients, so were eligible. The sensitivity, specificity, and accuracy of CT scanning in detecting N disease were 6%, 7%, and 76%, respectively. Predictive value of positive and negative tests were 8% and 86%, respectively. Among the patients who were diagnosed to have N disease in the preoperative evaluation by CT scanning and underwent exploration, patients (7%) had actual N disease, which was verified by postoperative histopathological examination (Fig ). Another patients (% of explored cn patients) were pno, 6 patients (%) were pn, and patients were pn, so the true-positive rate of CT scanning in the evaluation of N disease was only 7% and the falsepositive rate was % among the explored patients. Surgical Results in Clinically N Patients Among the 78 patients who were diagnosed to have N disease by preoperative evaluation by CT scanning, there were 8 patients in whom resection was not performed, including patients undergoing only exploratory thoracotomy due to extensive disease (see Table ). The reasons in the 7 patients who did not undergo surgical intervention were as follows: distant metastasis, 6; malignant pleural effusion, ; bulky N disease, 7; extensive invasion of mediastinal structures, 7; complications in major organs, ; and refusal of operation,. The most common histological cell type in the nonresection group was adenocarcinoma (8/8), followed by epidermoid carcinoma (/8) (see Table ). Excluding the cases of exploratory thoracotomy, 6 patients with true N disease (cn-pn) underwent curative and noncurative operations (% each) (see Table ). When their cell types were compared, curative operation could be more frequently accomplished in patients with epidermoid carcinoma (/, 7%) than in those with adenocarcinoma (/, %). The survival curves of the patients in this group are shown in Figure. The -year survival rate of the patients with pn and pn disease were 68% and %, respectively. On the other hand, the -year survival rate of patients with pn disease was 6%, including six operative deaths, and it was % in curatively resected patients, including three operative deaths. There were significant differences between pn and pno disease, and between pn and pn disease, respectively. There were no -year survivors among the patients with cn-pn disease who were incompletely resected, but patients ( with adenocarcinoma and with adenosquamous carcinoma; who underwent postoperative radiotherapy and who did not) have survived more than years after the operation. Surgical Results of Clinically N& but Postoperatively N Patients. There were 7 patients whose preoperative stage was NO or N, but in whom N disease was discovered at thoracotomy or by postoperative pathological examination of the lymph nodes removed (see Table ). Their preoperative evaluations of the N factor were NO in patients and N in patients, and their preoperative staging was as follows: stage in patients, stage in patients, stage A in patients, and stage B in patients. Thirty-one patients (66%) underwent curative operations, and this rate was higher than that in patients with cn-pn disease (%). Noncurative operation was more common in the preoperatively stage A and B group than in those with stage and disease. Histological diagnoses for these 7 patients are shown in Table. Adenocarcinoma was the most frequent, followed by epidermoid carcinoma. Of the 7 patients, had a curative operation and 6 had a noncurative operation. The survival curve of the 7 patients in this group is shown in Figure. The -year survival rate of this group overall (n = 7) was 7%, and it was % if the 6 patients who underwent noncurative operations (the longest survival was 8 months) were excluded. Overall Surgical Results of Patients With Postoperatively N Disease n all, there were 7 patients with N disease including 8 (% of N patients) inoperable N patients (Fig ). There were resected patients (6%) with postoperatively N disease, and of these patients 6 had truepositive disease and 7 had false-negative disease on CT. Their histological diagnoses are shown in Table. Seventy-five had adenocarcinoma and had epidermoid carcinoma. Eighty-four patients underwent curative operation (% of N patients) and 6 had a noncurative operation. The survival curves are shown in Figure. The overall -year survival rate of the patients was 7%, and that of the 8 patients undergoing curative operation was %. When the -year survival rates of the curatively resected patients with true-positive disease (n = ) and

5 Ann Thorac Surg ;:?-6 WATANABE ET AL 7 N NON-SMALL CELL LUNG CANCER cn 68% % pn(curative op.) c... (overall) % 6% 6 8 months 6o Fig. Survival curves of clinically N patients classified by the postoperative N factor. Operative deaths were included in the calculation of all survival rates in this and the other figures. (A = alive with no evidence of disease; A = dead with no evidence of disease; pno = patients with clinical N disease but postsurgically NO [n = ; pn = patients with clinical N disease but postsurgically N fn = 6; pn = patients with clinical N disease and postsurgically N [n = 6.) those with compared, there was groups. false-negative disease (n = ) on CT were they were % and %, respectively, but no significant difference between the two The -year survival rates of the patients with adenocarcinoma (n = ) and epidermoid carcinoma (n = 6) were % and %, respectively, showing no significant difference between the two. The -year survival rates of the Q) - E - a.- > v) 8- - c-: 6- i - *'!..., c... CNO-- (curative op.) pn +...:... (overall) L% % 6 8 months6' Fig. Survival curves of patients with clinically unrecognized N disease (clinical stage NO or N). (curative op. = patients undergoing curative operation fn = ; overall = patients undergoing curative operation plus those with noncurative operation [n = 7.)

6 8 WATANABE ET AL N NON-SMALL CELL LUNG CANCER Ann Thorac Surg ;: PN Total 7(%) patients with metastases confined within one level and those with metastases extending more than two levels were % and 7%, respectively, but there was no significant difference between the two groups. 8(%)... Noncurative op. (%) J Comment A major factor affecting the prognosis of patients undergoing operation for lung cancer is the presence of lymph node metastases and their location. There should be no objection to the statement that definitive surgical treat ment is the treatment of first choice for patients with stage Fig. Distribution of 7 patients with N disease. f* Nine patients undergoing explorato y thoracotomy were included.) (cn = patients with clinically proven N disease; cn- = patients with clinically unrecognized N disease.) patients with T N MO (n = ) and T N MO disease (n = ) were % and %, respectively, whereas those of patients with T N MO (n = 6) and T N MO disease (n = ) were % and, respectively. However, there were no significant differences between either T N MO versus T N MO, T N versus T N MO, or T N MO versus T N MO. Excluding T N MO patients, a comparison was made in respect to number of metastatic levels (there were patients who had multiple metastatic lymph nodes within one level; however, they were calculated as one metastatic focus in this comparison). The -year survival rates of the and non-small cell lung cancer. However, there exists considerable controversy regarding the treatment of patients with mediastinal lymph node metastases. There are many physicians who do not regard surgical treatment as a valid option in patients with mediastinal node metastases, but we do not support this concept. Even among surgeons, there still exists controversy regarding the selection criteria for surgical intervention in patients with N disease [lo, 6. We have been taking an aggressive attitude toward surgical treatment in patients with mediastinal lymph node metastases. To allow more complete dissection of the mediastinal lymph nodes, extensive operative procedures have been applied in the past years. As a result, there definitively was a group of patients with N disease who could undergo curative operations and gained long-term survival, even though it was a small part of the whole patient population with N disease. n the preoperative evaluation of N disease, two alternative methods are used. One is noninvasive, using cn months % % % Fig. Survival curves of patients with N disease undergoing curative operation. (cn- = patients with clinically unrecognized N disease fn = ; cn = patients with clinically proven N disease fn = ; symbols as in Figure.)

7 Ann Thorac Surg ::-6 WATANABE ET AL N NON-SMALL CELL LUNG CANCER conventional tomograms, CT scanning, scintiscanning, or magnetic resonance imaging. The other is the use of invasive procedures, such as mediastinal exploration or mediastinoscopy. We did not employ mediastinoscopy, and CT scanning was used for the selection of our surgical candidates. Except for patients with bulky N disease, an aggressive attitude toward surgical intervention was taken, even if N disease was found preoperatively by CT scanning. t should be mentioned that the true-positive rate of CT in our present series was only 7% ( of explored patients), and the false-positive rate was 8%. Among these explored cn-pn patients, only patients (7.8%) had a exploratory thoracotomy due to unresectable disease. f all the patients in our series with N disease detected by preoperative CT scanning were uniformly excluded from operation (as some physicians are doing), % of pno or pn patients would have been excluded. Because these patients have respective -year survival rates of 68% and % (including incompletely resected patients), they should not be denied the most appropriate treatment modality. t should be remembered that the reported values of the sensitivity, accuracy, and predictive value of CT scanning in detecting N disease are relatively low, as was also observed in our present study. Whittlesey [ 7 employed CT scanning in the staging of lung cancer and reported that mediastinal lymph nodes larger than. cm were positive for tumor in 6.6%, nodes between. and. cm were positive in.8%, and nodes less than. cm were positive in.7%. He concluded that all patients with otherwise resectable disease and eblarged mediastinal lymph nodes (greater than. cm) should undergo surgical exploration before resection is ruled out, as the false-positive rate for enlarged nodes was significant. Moreover, Martini and Flehinger [] have also reported that even when enlarged lymph nodes are found by CT scanning, many lung cancers are still resectable, and that more importantly, % to % of enlarged nodes detected by CT scanning are found to be hyperplastic and without metastasis. Magnetic resonance imaging has been expected to improve the accuracy of diagnosis of N disease, but Martini and associates [8] reported that there was no advantage of magnetic resonance imaging over CT scanning. Thus, both our present results and the data from these reports indicate that an aggressive attitude to surgical intervention is justified, even if lymphadenopathy is demonstrated in the mediastinum by preoperative CT scanning, provided that the suspected N disease is not unresectably bulky. There were only 7 patients with bulky unresectable N disease who did not undergo operation in our series. Although the accuracy of preoperative diagnosis may be increased by the combined use of preoperative mediastinal exploration (eg, mediastinoscopy), we did not use mediastinoscopy as a routine method of preoperative investigation. Pearson and co-workers [, employed mediastinoscopy in selecting patients for surgical exploration and reported that the -year survival rate of the patients with N disease detected by mediastinoscopy (n = 7) was %. However, when mediastinoscopy was negative and N nodal involvement was found only at thoracotomy (n = 6), the actuarial survival rate was %. They did not mention the overall -year survival rate of their patients, but these results were not so different from those obtained in our series without mediastinoscopy in selection of surgical candidates (7% overall and % for curatively resected patients). Our data showed little difference in survival rates between patients whose N disease was detected before operation and those whose N disease was discovered at thoracotomy or by postoperative pathology studies, provided complete resection could be accomplished. We think, therefore, that bulky unresectable N disease can be satisfactorily detected by CT scanning alone, as there were only patients found to be unresectable at thoracotomy. Of course, there would be no objection to the use of mediastinoscopy in patient selection. Mediastinoscopy can be helpful in determining which clinically N patients may benefit from surgical exploration. However, there are some long-term survivors among mediastinoscopypositive patients [l,. Mediastinoscopy does not cover all the known lymph node stations, and it is not yet clear who is a surgical candidate among mediastinoscopypositive patients. n some reports, all medistinoscopypositive patients were not surgical candidates [], whereas other authors have stated that mediastinal node metastasis without fixation in one station was no contraindication to exploration []. f all of mediastinoscopypositive patients are uniformly excluded from operation, some patients who otherwise might be salvaged by surgical therapy will undergo inappropriate treatment. Various results of surgical treatment of N disease have been reported. Pearson [l] collected the reported results of resection in patients with mediastinal lymph node metastases identified preoperatively and found a range from % to % for the -year survival rate. Survival of patients with N disease identified intraoperatively ranges from % to %, and is better than that of those with clinically evident N disease. We would like to emphasize that the surgical indications for N disease should not be discussed only on the basis of the reported survival rates, and that it is vital to make a correct interpretation of these confusing reports of the results of operation. t is worth noting that the patient populations vary greatly between institutions and that these differences are even more marked between Japan and western countries. The different results reported from Japan and western countries are thought to depend on the following reasons. The first reason is a difference in the method of selection of patients with clinically proven N disease for operation. Many Japanese institutions (including our hospital) have a rather more aggressive attitude toward performing operation for clinically evident N disease than is evident in western countries. Second, our present series reports the experience of a surgical department, so most of the patients who had obviously inoperable disease (such as clinical evidence of metastasis to distant

8 6 WATANABE ET AL N NON-SMALL CELL LUNG CANCER Ann Thorac Surg ;:-6 organs, hoarseness, superior vena cava syndrome, palpable supraclavicular lymph nodes, or other unresectable disease) were excluded from admission. Owing to these reasons, among the patients with clinically evident N disease, 6 of patients (6%) underwent surgical resection. This rate is higher than that reported in the literature. Luke and colleagues [] explored only % of 86 patients positive for N disease before thoracotomy, and Martini and Flehinger [] explored 8% of 8 patients with clinically evident N disease. By the aggressive inclusion of surgical patients in our series, the ratio of resected patients with clinically proven N disease to all pn patients undergoing resection was increased. This could greatly bias the results of the overall surgical outcomes for N disease, because the rate of complete resection was much higher in the clinically unrecognized N group than in the clinically evident N group. f the number of patients with clinically evident N disease is much higher than the number with clinically unrecognized N disease (as it was in our series), the overall survival rate would be worse than if the series included a high incidence of patients with clinically unrecognized N disease. n our present series, the pn patients undergoing resection comprised 6 (6%) with clinically evident N disease and 7 (%) with clinically unrecognized N disease. n contrast, in Martini and Flehinger s series [], the pn patients undergoing resection comprised 7 (%) with clinically evident N disease and (6%) with clinically unrecognized N disease. When the survival rates were compared, the overall -year survival rate for the pn patients in our series was 7%, which corresponded with the result of Naruke and associates [8] of % (n = 6). However, the -year survival rates for N patients reported by Mountain [7] and Martini and Flehinger [] were 6%, and %, respectively. t must be remembered that both these reports gave the survival rates of the curatively resected group and not those of all patients, including the patients undergoing incomplete resection. The results for the 7 patients in Martini and Flehinger s [] series with incomplete resection were not described, but they could greatly reduce the survival rate if the overall survival rate of resected patients were calculated. n addition, their series contained a rather small number of patients with detectable N disease, which generally shows a worse prognosis than clinically unrecognized N disease. Another reason for the difference in the reported survival rate may concern the definitions of complete resection or curative operation. Martini and Flehinger [] reported that the -year survival rate of patients with completely resected N disease was %, whereas the figures obtained by Naruke and associates [8] and in our present series were % and %, respectively. However, survival rates can be greatly modified by the selection of the complete resection group at the time of evaluating the survival data. n our present series, the frequency of curative operation in patients with clinically evident N disease was 8% overall and 6% of explored patients. The frequency of curative operation in the patients with clinically unrecognized N disease was 66%. n total, 8 of N patients (%) undergoing resection underwent curative operation (see Fig ). n contrast, in the series of Martini and Flehinger [], only 7% (Y8) of clinically recognized N patients and 8% (7) of explored patients underwent complete resection. Furthermore, even among the patients with clinically unrecognized N disease, only out of resected patients (%) underwent complete resection. n all, only 8% (/) of their N patients undergoing resection had a complete resection procedure, a rate far lower than that in our series. The relatively high rate of curative resection in our present series might be partly due to our operative procedure of extensive mediastinal lymph node dissection, but there must also be some differences among these series in the definition of curative operation. Mountain [7] reported a 6% -year survival in patients with completely resected N disease, and defined complete resection as being achieved when the most distal nodes within each major lymphatic drainage region are microscopically free of tumor. f the farthest node in the dissection is positive for tumor, they defined the resection as incomplete. This definition, although it is not described in detail, is markedly different from our definition []. We defined complete resection as a procedure in which all accessible metastatic lymph nodes were removed, even if the most distal node was found to be involved. f we use Mountain s criteria to define complete resection, a considerable number of our patients are then excluded from the complete resection group, which results in an improvement of the survival rate of the complete resection group. There is thus an urgent need for international agreement regarding the definition of operative radicality so as to allow a more rational comparison of the surgical results. We have been adopting an aggressive attitude to clinically evident N disease, because the reported survival rates of nonsurgical treatment in patients with N disease were extremely low. The $year and -year survival rates of nonsurgically treated N patients in our series were 7% and %, respectively, and their % survival length was 6 months. Our present series supports the value of an aggressive attitude toward resection in patients with N disease. However, the results of surgical treatment of N disease shown by the present series were not satisfactory. To improve the resectability rate and ultimately the survival of patients with clinically evident N disease, neoadjuvant therapy has been attempted in several preliminary trials [,. We also have started such a clinical trial recently, but it is too early yet to make any clear conclusions regarding the survival rate. However, such therapy seems to improve the resection rate of bulky N disease. n conclusion, an aggressive attitude toward surgical intervention for N disease can be advocated. n patients with N disease detected either by preoperative investigations or at thoracotomy, complete resection should be performed whenever possible by employing extended surgical procedures to allow complete dissection of the mediastinal lymph nodes.

9 Ann Thorac Surg ;:-6 WATANABE ET AL 6 N NON-SMALL CELL LUNG CANCER References. Pearson FG. Mediastinal adenopathy-the N lesion. n: DeLarue NC. Eschapasse H, eds. nternational trends in general thoracic surgery, vol. Lung cancer. Philadelphia: WB Saunders, 8:.. Pearson FG, DeLarue NC, lves R, Todd TRJ, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 8;8:-.. Coughlin M, Deslauriers JD, Beaulieu M, et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg 8;:6-6.. Ratto GB, Mereu C, Motta G. The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer. Chest 88;:87-.. Luke WP, Pearson FG, Todd TRJ, Patterson GA, Cooper JD. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg 86;:. 6. Backer CL, Shields TW, Lockhart CG, Volgelzang R, LoCicero J. Selective preoperative evaluation for possible N disease in carcinoma of the lung. J Thorac Cardiovasc Surg 87;: Mountain CF. The biological operability of stage non-small cell lung cancer. Ann Thorac Surg 8;: Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 88;6: 6-.. Martini N, Flehinger BJ. The role of surgery in N lung cancer. Surg Clin N Am 87;67:7-.. Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N disease) in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg ;:8-.. Watanabe Y, Shimizu J, Tsubota M, wa T. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Chest ;7: -6.. The Japan Lung Cancer Society. General rule for clinical and pathological records of lung cancer. Tokyo: Kanahara Publishing Company, 86.. Watanabe Y, chihashi T, wa T. Median sternotomy as an approach for pulmonary surgery. Thorac Cardiovasc Surg 88;6:7-.. nternational Union Against Cancer. TNM classification of malignant tumours. th ed. New York: Springer-Verlag, 87.. American Joint Committee for Cancer Staging and End- Results Reporting. Staging of lung cancer 7. Chicago: American Joint Committee, Shields TW. Carcinoma of the lung. n: Shields TW, ed. General thoracic surgery. Philadelphia: Lea & Febiger, Whittlesey D. Prospective computed tomographic scanning in the staging of bronchogenic carcinoma. J Thorac Cardiovasc Surg 88;: Martini N, Heelan R, Westcott J, et al. Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma. J Thorac Cardiovasc Surg 8;:6-.. Faber LP, Kittle CF, Warren WH, et al. Preoperative chemotherapy and irradiation for stage non-small cell lung cancer. Ann Thorac Surg 8; Martini N, Kris MG, Gralla RJ, et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (NMO). Ann Thorac Surg 88;:7-.

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram

More information

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

L cancer-related deaths in Japan. The number of patients

L cancer-related deaths in Japan. The number of patients Extended Resection of the Left Atrium, Great Vessels, or Both for Lung Cancer Ryosuke Tsuchiya, MD, Hisao Asamura, MD, Haruhiko Kondo, MD, Tomoyuki Goya, MD, and Tsuguo Naruke, MD Division of Thoracic

More information

The Role of Radiation Therapy

The Role of Radiation Therapy The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative

More information

Lymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu, M.D.

Lymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu, M.D. ORIGINAL ARTICLES The Importance of Surgery to Non-Small Cell Carcinoma of Lung with Mediastinal Lymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu,

More information

Carcinoma of the Lung

Carcinoma of the Lung THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and

More information

AJCC-NCRA Education Needs Assessment Results

AJCC-NCRA Education Needs Assessment Results AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Significance of Metastatic Disease

Significance of Metastatic Disease Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.

More information

International Association for the Study of Lung Cancer lymph node map Lymph node stations Imaging CT

International Association for the Study of Lung Cancer lymph node map Lymph node stations Imaging CT Review of the International Association for the Study of Lung Cancer Lymph Node Classification System Localization of Lymph Node Stations on CT Imaging Hamza Jawad, MBBS a, Arlene Sirajuddin, MD b, Jonathan

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

CT Depiction of Regional Nodal Stations for Lung Cancer Staging

CT Depiction of Regional Nodal Stations for Lung Cancer Staging ownloaded from www.ajronline.org by 37.44.204.189 on 11/24/17 from IP address 37.44.204.189. opyright RRS. For personal use only; all rights reserved T epiction of Regional Nodal Stations for Lung ancer

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Site of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma

Site of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,

More information

Collaborative Stage. Site-Specific Instructions - LUNG

Collaborative Stage. Site-Specific Instructions - LUNG Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

MEDIASTINAL STAGING surgical pro

MEDIASTINAL STAGING surgical pro MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical

More information

P sumed to have early lung disease with a favorable

P sumed to have early lung disease with a favorable Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,

More information

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED

More information

GUIDELINES FOR CANCER IMAGING Lung Cancer

GUIDELINES FOR CANCER IMAGING Lung Cancer GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for

More information

Karoline Nowillo, MD. February 1, 2008

Karoline Nowillo, MD. February 1, 2008 Case Presentation Karoline Nowillo, MD SUNY Downstate t February 1, 2008 Case Presentation Chief complaint enlarging goiter x 8 months History of present illness shortness of breath, heaviness in chest

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Mediastinal biopsy for indeterminate chest lesions

Mediastinal biopsy for indeterminate chest lesions Thorax (1966), 21, 533. Mediastinal biopsy for indeterminate chest lesions STEBBINS B. CHANDOR, EDWARD A. STEMMER, JAMES W. CALVIN, AND JOHN E. CONNOLLY Fronm the Department of Surgery, University of California

More information

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery. Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This

More information

Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital

Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,

More information

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21364

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

SETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.

SETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD. OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer

Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Yukinori Sakao, MD, PhD, Hideaki Miyamoto, MD, PhD, Akio Yamazaki, MD, PhD, Tsumin Oh, MD, Ryuta

More information

Controversies in management of squamous esophageal cancer

Controversies in management of squamous esophageal cancer 2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous

More information

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung

More information

Carcinoma of the Lung in Women

Carcinoma of the Lung in Women Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph

More information

Imaging in gastric cancer

Imaging in gastric cancer Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.

More information

Video-Mediastinoscopy Thoracoscopy (VATS)

Video-Mediastinoscopy Thoracoscopy (VATS) Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

The 8th Edition Lung Cancer Stage Classification

The 8th Edition Lung Cancer Stage Classification The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report

More information

Staging of lung cancer provides a common language

Staging of lung cancer provides a common language The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International

More information

Reoperative central neck surgery

Reoperative central neck surgery Reoperative central neck surgery R. Pandev, I. Tersiev, M. Belitova, A. Kouizi, D. Damyanov University Clinic of Surgery, Section Endocrine Surgery University Hospital Queen Johanna ISUL Medical University

More information

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,

More information

Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease)

Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease) Eur J Cardio-thorac Surg (1996) 10:649-655 Springer-Verlag 1996 P. De Leyn P. Schoonooghe G. Deneffe D. Van Raemdonck W. Coosemans J. Vansteenkiste T. Lerut Surgery for non-small cell lung cancer with

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

DESCRIPTION: This is the part of the trunk, which is located between the root of the neck and the superior border of the abdominal region.

DESCRIPTION: This is the part of the trunk, which is located between the root of the neck and the superior border of the abdominal region. 1 THE THORACIC REGION DESCRIPTION: This is the part of the trunk, which is located between the root of the neck and the superior border of the abdominal region. SHAPE : T It has the shape of a truncated

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Lymph node metastasis is one of the most important prognostic

Lymph node metastasis is one of the most important prognostic ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan

More information

Dr. Weyrich G07: Superior and Posterior Mediastina. Reading: 1. Gray s Anatomy for Students, chapter 3

Dr. Weyrich G07: Superior and Posterior Mediastina. Reading: 1. Gray s Anatomy for Students, chapter 3 Dr. Weyrich G07: Superior and Posterior Mediastina Reading: 1. Gray s Anatomy for Students, chapter 3 Objectives: 1. Subdivisions of mediastinum 2. Structures in Superior mediastinum 3. Structures in Posterior

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

Lung Cancer Clinical Guidelines: Surgery

Lung Cancer Clinical Guidelines: Surgery Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with

More information

Lung Cancer: Determining Resectability

Lung Cancer: Determining Resectability Lung Cancer: Determining Resectability Leslie E. Quint lequint@umich.edu No disclosures Lung Cancer: Determining Resectability AIM: Review imaging features that suggest resectability / unresectability

More information

A Prospective Study of Indications for Mediastinoscopy in Lung Cancer With CT Findings, Tumor Size, and Tumor Markers

A Prospective Study of Indications for Mediastinoscopy in Lung Cancer With CT Findings, Tumor Size, and Tumor Markers GENERAL THORACIC A Prospective Study of Indications for Mediastinoscopy in Lung Cancer With CT Findings, Tumor Size, and Tumor Markers Hideki Kimura, MD, PhD, Naomichi Iwai, MD, PhD, Soichiro Ando, MD,

More information

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper

More information

T lung cancer cases per year in the United States to be

T lung cancer cases per year in the United States to be CURRENT REVIEW Surgical Treatment for Higher Stage Non-Small Cell Lung Cancer Dirk E. Van Raemdonck, MD, Airton Schneider, MD, and Robert J. Ginsberg, MD Sloan-Kettering Institute; Department of Thoracic

More information

Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer

Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Original Article on Transbronchial Needle Aspiration (TBNA) Standardized transbronchial needle aspiration procedure for intrathoracic lymph node staging of non-small cell lung cancer Xu-Ru Jin 1 *, Min

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Tumour size as a prognostic factor after resection of lung carcinoma

Tumour size as a prognostic factor after resection of lung carcinoma Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Surgical management of lung cancer

Surgical management of lung cancer Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary

More information

Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures

Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Review Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Hiroaki Nomori, MD, PhD, Kazunori Iwatani, MD, Hironori Kobayashi, MD, Atsushi Mori, MD, and

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566

More information

Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy

Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,

More information

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

Induction chemotherapy followed by surgical resection

Induction chemotherapy followed by surgical resection Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser

More information

Carinal resections. Leonidas Tapias, Michael Lanuti. Clinical vignette

Carinal resections. Leonidas Tapias, Michael Lanuti. Clinical vignette Masters of Cardiothoracic Surgery Carinal resections Leonidas Tapias, Michael Lanuti Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA Correspondence to: Michael Lanuti, MD.

More information

Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping

Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping GCTAB Column Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping Yi-Nan Dong, Nan Sun, Yi Ren, Liang Zhang, Ji-Jia Li, Yong-Yu Liu Department

More information

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals 6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy

More information

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000

More information

Interstitial Irradiation for Unresectable Carcinoma of the Lung

Interstitial Irradiation for Unresectable Carcinoma of the Lung THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 20 NUMBER 5 NOVEMBER 1975 Interstitial Irradiation for Unresectable Carcinoma

More information

EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY

EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY Morihito Okada, MD Noriaki Tsubota, MD Masahiro Yoshimura, MD Yoshifumi Miyamoto, MD Hidehito Matsuoka, MD, Shinsuke Satake, MD

More information

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma. Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest

More information

PET CT for Staging Lung Cancer

PET CT for Staging Lung Cancer PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct

More information

ABSTRACT. Journal of Radiation Research, Vol. 58, No. 1, 2017, pp doi: /jrr/rrw076 Advance Access Publication: 8 September 2016

ABSTRACT. Journal of Radiation Research, Vol. 58, No. 1, 2017, pp doi: /jrr/rrw076 Advance Access Publication: 8 September 2016 Journal of Radiation Research, Vol. 58, No. 1, 2017, pp. 86 105 doi: 10.1093/jrr/rrw076 Advance Access Publication: 8 September 2016 The Japan Lung Cancer Society Japanese Society for Radiation Oncology

More information

Treatment of Inoperable Lung Carcinoma: A Combined Modality Approach

Treatment of Inoperable Lung Carcinoma: A Combined Modality Approach Treatment of Inoperable ung Carcinoma: A Combined Modality Approach Hiroshi Takita, M.D., Ariel C. Hollinshead, h.d., Donna J. Rizzo, R.N., Christine M. Kramer, M.S., Tah Y. Chen, M.D., Joginder N. Bhayana,

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information